Literature DB >> 10927841

Fulminant hepatitis A in patients with chronic liver disease.

P Lefilliatre1, J P Villeneuve.   

Abstract

Fulminant hepatitis is a rare complication of acute hepatitis A virus (HAV) infection. We report three cases of fulminant hepatic failure with death due to HAV infection in patients with pre-existing chronic liver disease. Data from the literature also indicate a high case fatality rate during HAV superinfection in patients with chronic hepatitis B, particularly those with cirrhosis, and in patients with alcoholic cirrhosis. In patients with chronic hepatitis C, results are conflicting with some reports indicating a high fatality rate of HAV superinfection and others not, irrespective of the presence or absence of cirrhosis. Based on our observations and this review of the literature, we suggest that patients with chronic liver disease should be vaccinated against hepatitis A.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10927841

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  14 in total

1.  Seroprevalence and risk factors for hepatitis A among Montreal street youth.

Authors:  Elise Roy; Nancy Haley; Pascale Leclerc; Lyne Cédras; Lucie Bédard; Robert Allard
Journal:  Can J Public Health       Date:  2002 Jan-Feb

2.  Seroprevalence of anti-HAV among patients with chronic viral liver disease.

Authors:  Hyun Chin Cho; Seung Woon Paik; Yu Jin Kim; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Byung Chul Yoo; Hee Jung Son; Seon Woo Kim
Journal:  World J Gastroenterol       Date:  2011-01-14       Impact factor: 5.742

3.  Optimizing Immunization Strategies in Adult Patients With Chronic Liver Disease and Liver Transplant Recipients.

Authors:  Stacey Rolak; Adnan Said; Rita German; Mary S Hayney; Freddy Caldera
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04

Review 4.  Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols.

Authors:  Andrea Duchini; John A Goss; Saul Karpen; Paul J Pockros
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

5.  Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.

Authors:  Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris
Journal:  MMWR Recomm Rep       Date:  2020-07-03

6.  Etiological investigation of fatal liver failure during the course of chronic hepatitis B in southeast China.

Authors:  Wei-Min Ke; Xue-Jun Li; Li-Na Yu; Jing Lai; Xiao-He Li; Zhi-Liang Gao; Pei-Jia Chen
Journal:  J Gastroenterol       Date:  2006-04       Impact factor: 6.772

7.  Comparison of the Clinical Features of Hepatitis A between HBsAg-Positive and HBsAg-Negative Patients.

Authors:  Kwang Min Kim; Sung June Eo; Geum-Youn Gwak; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Byung Chul Yoo; Seung Woon Paik
Journal:  Gut Liver       Date:  2011-11-21       Impact factor: 4.519

8.  Clinical characteristics of acute hepatitis A outbreak in Taiwan, 2015-2016: observations from a tertiary medical center.

Authors:  Nan-Yu Chen; Zhuo-Hao Liu; Shian-Sen Shie; Tsung-Hsing Chen; Ting-Shu Wu
Journal:  BMC Infect Dis       Date:  2017-06-20       Impact factor: 3.090

9.  Hepatitis A infection in patients with chronic viral liver disease: a cross-sectional study in Jahrom, Iran.

Authors:  A Ahmadi Vasmehjani; D Javeshghani; R Baharlou; M Shayestehpour; S D Mousavinasab; N Joharinia; S E Enderami
Journal:  Epidemiol Infect       Date:  2014-04-17       Impact factor: 4.434

Review 10.  Emerging need for vaccination against hepatitis A virus in patients with chronic liver disease in Korea.

Authors:  Hyun Joo Song; Tae Hun Kim; Ji Hyun Song; Hee Jung Oh; Kum Hei Ryu; Hye Jung Yeom; Seong-Eun Kim; Hye-Kyung Jung; Ki-Nam Shim; Sung-Ae Jung; Kwon Yoo; Il-Hwan Moon; Kyu Won Chung
Journal:  J Korean Med Sci       Date:  2007-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.